LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 26

Suchoptionen

Artikel ; Online: Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?

Elias, Roy / Antonarakis, Emmanuel S

2023 Band 12, Heft 10, Seite(n) 2448–2453

Sprache	Englisch
Erscheinungsdatum	2023-10-03
Erscheinungsland	China
Dokumenttyp	Editorial ; Comment
ZDB-ID	2901601-0
ISSN	2219-6803 ; 2218-676X
ISSN (online)	2219-6803
ISSN	2218-676X
DOI	10.21037/tcr-23-1279
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel: Kidney Cancer Updates from the 2023 American Society of Clinical Oncology Annual Meeting in Chicago.

Elias, Roy / Ged, Yasser / Singla, Nirmish

Kidney cancer journal : official journal of the Kidney Cancer Association

2024 Band 21, Heft 2, Seite(n) 58–63

Abstract: This report highlights key research from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) across clinical trials and translational studies. ... ...

Abstract	This report highlights key research from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, with a focus on clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) across clinical trials and translational studies. Essential updates in the metastatic ccRCC clinical space encompass results from the CONTACT-03 study, which evaluated an immunotherapy containing regimen for patients who progressed on an initial immunotherapy containing regimen, alongside updated results from the KEYNOTE-426 and CLEAR trials. In the metastatic nccRCC domain, we review clinical trials of combination immunotherapies and tyrosine kinase inhibitors (TKIs). Additionally, we highlight exciting early-phase studies exploring novel targets in RCC and engineered T-cell methodologies. Finally, we summarize notable efforts in translational research, emphasizing biomarker investigations to determine predictors of immunotherapy response, the application of molecular classifiers in RCC, and the relationship between the microbiome and RCC. There were many important RCC related abstracts presented at this year's ASCO conference, attesting to the continued momentum of research in the field. All conference materials, including abstracts and presentations, can be accessed online through the conference website.
Sprache	Englisch
Erscheinungsdatum	2024-01-17
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2244563-8
ISSN	1933-0871 ; 1933-0863
ISSN (online)	1933-0871
ISSN	1933-0863
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel: Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine.

Elias, Roy / Sharma, Akanksha / Singla, Nirmish / Brugarolas, James

Kidney cancer journal : official journal of the Kidney Cancer Association

2020 Band 17, Heft 4, Seite(n) 94–104

Sprache	Englisch
Erscheinungsdatum	2020-04-01
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2244563-8
ISSN	1933-0871 ; 1933-0863
ISSN (online)	1933-0871
ISSN	1933-0863
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities.

Elias, Roy / Zhang, Qing / Brugarolas, James

Cancer journal (Sudbury, Mass.)

2020 Band 26, Heft 5, Seite(n) 390–398

Abstract: The discovery of the von Hippel-Lindau (VHL) gene marked a milestone in our understanding of clear cell renal cell carcinoma (ccRCC) pathogenesis. VHL inactivation is not only a defining feature of ccRCC, but also the initiating event. Herein, we discuss ...

Abstract	The discovery of the von Hippel-Lindau (VHL) gene marked a milestone in our understanding of clear cell renal cell carcinoma (ccRCC) pathogenesis. VHL inactivation is not only a defining feature of ccRCC, but also the initiating event. Herein, we discuss canonical and noncanonical pVHL functions, as well as breakthroughs shaping our understanding of ccRCC evolution and evolutionary subtypes. We conclude by presenting evolving strategies to therapeutically exploit effector mechanisms downstream of pVHL.
Mesh-Begriff(e)	Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/therapy ; Genes, Tumor Suppressor ; Humans ; Kidney Neoplasms/genetics ; Kidney Neoplasms/therapy ; Von Hippel-Lindau Tumor Suppressor Protein/genetics
Chemische Substanzen	Von Hippel-Lindau Tumor Suppressor Protein (EC 2.3.2.27) ; VHL protein, human (EC 6.3.2.-)
Sprache	Englisch
Erscheinungsdatum	2020-09-24
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
ZDB-ID	2018400-1
ISSN	1540-336X ; 1528-9117 ; 1081-4442
ISSN (online)	1540-336X
ISSN	1528-9117 ; 1081-4442
DOI	10.1097/PPO.0000000000000480
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 4470: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 163: Hefte anzeigen

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma.

Sharma, Akanksha / Elias, Roy / Christie, Alana / Williams, Noelle S / Pedrosa, Ivan / Bjarnason, Georg A / Brugarolas, James

Kidney cancer (Clifton, Va.)

2023 Band 7, Heft 1, Seite(n) 15

Abstract: This corrects the article DOI: 10.3233/KCA-210117.]. ...

Abstract	[This corrects the article DOI: 10.3233/KCA-210117.].
Sprache	Englisch
Erscheinungsdatum	2023-03-23
Erscheinungsland	United States
Dokumenttyp	Published Erratum
ZDB-ID	2961890-3
ISSN	2468-4570 ; 2468-4562
ISSN (online)	2468-4570
ISSN	2468-4562
DOI	10.3233/KCA-229030
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset.

Baraban, Ezra G / Elias, Roy / Lin, Ming-Tseh / Ged, Yasser / Zhu, Jing / Pallavajjala, Aparna / Singla, Nirmish / Lotan, Tamara L / Argani, Pedram / Eshleman, James R / Epstein, Jonathan I

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

2024 Band 37, Heft 5, Seite(n) 100472

Abstract: Chromophobe renal cell carcinoma (ChRCC) is the third most common subtype of renal cell carcinoma and typically exhibits indolent behavior, though a rare subset can exhibit high-grade morphologic features and is associated with a poor prognosis. Although ...

Abstract	Chromophobe renal cell carcinoma (ChRCC) is the third most common subtype of renal cell carcinoma and typically exhibits indolent behavior, though a rare subset can exhibit high-grade morphologic features and is associated with a poor prognosis. Although there are limited data on the molecular characteristics of metastatic and sarcomatoid ChRCC, the molecular features of high-grade, nonsarcomatoid ChRCC remain unexplored. Herein, we characterize 22 cases of ChRCC with high-grade, nonsarcomatoid components. High-grade ChRCC frequently demonstrated advanced stage at diagnosis (64% ≥pT3a or N1), with regions of extrarenal extension, nodal metastases, and vascular invasion consisting solely of high-grade ChRCC morphologically. We performed spatially guided panel-based DNA sequencing on 11 cases comparing high-grade and low-grade regions (n = 22 samples). We identified recurring somatic alterations emblematic of ChRCC, including deletions of chromosomes 1, 2, 6, 10, 13, 17, and 21 in 91% (10/11) of cases and recurring mutations in TP53 (81.8%, n = 9/11) and PTEN (36.4%, n = 4/11). Notably, although PTEN and TP53 alterations were found in both high-grade and low-grade regions, private mutations were identified in 3 cases, indicating convergent evolution. Finally, we identified recurring RB1 mutations in 27% (n = 3) of high-grade regions leading to selective protein loss by immunohistochemistry not observed in adjacent low-grade regions. This finding was confirmed in The Cancer Genome Atlas cohort where 2 of 66 cases contained RB1 mutations and demonstrated unequivocal high-grade, nonsarcomatoid morphology. We also detected multiple chromosomal gains confined to the high-grade regions, consistent with imbalanced chromosome duplication. These findings broaden our understanding of the molecular pathogenesis of ChRCC and suggest that subclonal RB1 mutations can drive the evolution to high-grade, nonsarcomatoid ChRCC.
Mesh-Begriff(e)	Humans ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/pathology ; Kidney Neoplasms/genetics ; Kidney Neoplasms/pathology ; Middle Aged ; Female ; Male ; Aged ; Adult ; Neoplasm Grading ; Mutation ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/analysis ; Aged, 80 and over
Sprache	Englisch
Erscheinungsdatum	2024-03-14
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	645073-8
ISSN	1530-0285 ; 0893-3952
ISSN (online)	1530-0285
ISSN	0893-3952
DOI	10.1016/j.modpat.2024.100472
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2450: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back.

Elias, Roy / Kapur, Payal / Pedrosa, Ivan / Brugarolas, James

Clinical genitourinary cancer

2018 Band 16, Heft 6, Seite(n) 485–488

Mesh-Begriff(e)	Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Chemoradiotherapy/methods ; Clinical Deterioration ; Fatal Outcome ; Hospices ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/secondary ; Lung Neoplasms/therapy ; Male ; Pleural Effusion, Malignant/diagnostic imaging ; Pleural Effusion, Malignant/pathology ; Pleural Effusion, Malignant/therapy ; Radiosurgery ; Treatment Outcome ; Tumor Burden/drug effects ; Tumor Burden/radiation effects
Sprache	Englisch
Erscheinungsdatum	2018-07-20
Erscheinungsland	United States
Dokumenttyp	Case Reports ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2018.07.015
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 6168: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.

Sharma, Akanksha / Elias, Roy / Christie, Alana / Williams, Noelle S / Pedrosa, Ivan / Bjarnason, Georg A / Brugarolas, James

Kidney cancer (Clifton, Va.)

2022 Band 6, Heft 1, Seite(n) 69–79

Abstract: Background: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other ... ...

Abstract	Background: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other TKIs has been shown to afford added disease control. Objective: We sought to evaluate whether dose escalation of cabozantinib (Cabometyx Methods: We identified patients with mRCC at the University of Texas Southwestern Medical Center who were treated with cabozantinib dose escalation to 80 mg after progressing on conventional cabozantinib 60 mg. We then queried leading kidney cancer investigators across the world to identify additional patients. Finally, we reviewed pharmacokinetic (PK) data to assess how higher doses impacted circulating levels by comparison to other formulations (Cometriq Results: We report six patients treated at two different institutions with cabozantinib-responsive disease and good tolerability, where cabozantinib was dose escalated (typically to 80 mg, but as high as 120 mg) after progression on 60 mg, a strategy that resulted in added disease control (median duration, 14 months; 95% Confidence Interval [CI]: 8 - Not Estimable[NE]). Four patients (66.7%) had disease control lasting at least 1 year. No grade III/IV adverse events were identified in this small, select, cohort. A comparison of PK data to FDA-approved cabozantinib 140 mg capsules suggest that cabozantinib 80 mg tablets results in comparable exposures. Conclusions: mRCC patients with cabozantinib responsive disease and reasonable tolerability may benefit from dose escalation at progression.
Sprache	Englisch
Erscheinungsdatum	2022-03-15
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2961890-3
ISSN	2468-4570 ; 2468-4562
ISSN (online)	2468-4570
ISSN	2468-4562
DOI	10.3233/kca-210117
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.

Yin, Jianyi / Elias, Roy / Peng, Lan / Levonyak, Nicholas / Asokan, Annapoorani / Christie, Alana / Kubiliun, Nisa / Brugarolas, James / Hammers, Hans J

Clinical genitourinary cancer

2022 Band 20, Heft 3, Seite(n) 260–269

Abstract: Introduction: Immune checkpoint inhibitors (ICIs) have become a standard of care in metastatic renal cell carcinoma (mRCC) but are associated with immune-related adverse events (irAEs) including colitis. Growing evidence suggests proton pump inhibitors ( ...

Abstract	Introduction: Immune checkpoint inhibitors (ICIs) have become a standard of care in metastatic renal cell carcinoma (mRCC) but are associated with immune-related adverse events (irAEs) including colitis. Growing evidence suggests proton pump inhibitors (PPIs) increase the risk of inflammatory bowel disease (IBD). Given the pathophysiological overlap between IBD and ICI colitis, we sought to evaluate the relationship between PPI use and ICI colitis in mRCC patients. Patients and methods: We performed a retrospective study of adult patients who received ICI therapy for mRCC between 2015 and 2018 at University of Texas Southwestern Medical Center affiliated hospitals. Clinical characteristics, oncological outcomes, ICI colitis details, and PPI use details were collected by manual chart review. The diagnosis of ICI colitis was made via biopsy when available, or by clinical criteria (symptoms and response to immunosuppressive therapy) when biopsy specimens were unavailable or inconclusive. Univariable and multivariable logistic regression analyses were conducted to assess the potential contribution of PPIs to ICI colitis. Results: A total of 176 patients received ICI therapy for mRCC, of which 16 (9.1%) were diagnosed with ICI colitis. Patients with ICI colitis presented with elevated stool lactoferritin and calprotectin and a wide range of endoscopic and histologic findings. There were no significant differences between patients with and without ICI colitis in age, gender, medical comorbidities, RCC history, and overall survival. However, exposure to ipilimumab and PPI use were more frequently observed in patients with ICI colitis than those without. In univariable and multivariable logistic regression analyses, exposure to ipilimumab and chronic use of PPIs > 8 weeks were significantly associated with ICI colitis. Conclusion: In addition to ipilimumab use, chronic use of PPIs may be associated with ICI colitis in patients with mRCC.
Mesh-Begriff(e)	Adult ; Carcinoma, Renal Cell/drug therapy ; Colitis/chemically induced ; Colitis/drug therapy ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Inflammatory Bowel Diseases/drug therapy ; Ipilimumab/therapeutic use ; Kidney Neoplasms/drug therapy ; Proton Pump Inhibitors/adverse effects ; Retrospective Studies
Chemische Substanzen	Immune Checkpoint Inhibitors ; Ipilimumab ; Proton Pump Inhibitors
Sprache	Englisch
Erscheinungsdatum	2022-02-01
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2022.01.017
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 6168: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma.

Alam, Ridwan / Rezaee, Michael E / Pallauf, Maximilian / Elias, Roy / Yerrapragada, Anirudh / Enikeev, Dmitry / Fang, Dong / Shariat, Shahrokh F / Woldu, Solomon L / Ged, Yasser M A / Singla, Nirmish

Urologic oncology

2023 Band 41, Heft 11, Seite(n) 460.e1–460.e9

Abstract: Purpose: Racially driven outcomes in cancer are challenging to study. Studies evaluating the impact of race in renal cell carcinoma (RCC) outcomes are inconsistent and unable to disentangle socioeconomic disparities from inherent biological differences. ...

Abstract	Purpose: Racially driven outcomes in cancer are challenging to study. Studies evaluating the impact of race in renal cell carcinoma (RCC) outcomes are inconsistent and unable to disentangle socioeconomic disparities from inherent biological differences. We therefore seek to investigate socioeconomic determinants of racial disparities with respect to overall survival (OS) when comparing Black and White patients with RCC. Methods: We queried the National Cancer Database (NCDB) for patients diagnosed with RCC between 2004 and 2017 with complete clinicodemographic data. Patients were examined across various stages (all, cT1aN0M0, and cM1) and subtypes (all, clear cell, or papillary). We performed Cox proportional hazards regression with adjustment for socioeconomic and disease factors. Results: There were 386,589 patients with RCC, of whom 46,507 (12.0%) were Black. Black patients were generally younger, had more comorbid conditions, less likely to be insured, in a lower income quartile, had lower rates of high school completion, were more likely to have papillary RCC histology, and more likely to be diagnosed at a lower stage of RCC than their white counterparts. By stage, Black patients demonstrated a 16% (any stage), 22.5% (small renal mass [SRM]), and 15% (metastatic) higher risk of mortality than White patients. Survival differences were also evident in histology-specific subanalyses. Socioeconomic factors played a larger role in predicting OS among patients with SRMs than in patients with metastasis. Conclusions: Black patients with RCC demonstrate worse survival outcomes compared to White patients across all stages. Socioeconomic disparities between races play a significant role in influencing survival in RCC.
Mesh-Begriff(e)	Humans ; Black People ; Carcinoma, Renal Cell/epidemiology ; Carcinoma, Renal Cell/ethnology ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Kidney Neoplasms/epidemiology ; Kidney Neoplasms/ethnology ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Socioeconomic Factors ; White People ; Health Inequities ; Social Determinants of Health/ethnology ; Social Determinants of Health/statistics & numerical data
Sprache	Englisch
Erscheinungsdatum	2023-09-14
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2023.08.016
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 4817: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen